Eric Bleickardt
About Eric Bleickardt
Eric Bleickardt is the Vice President of Late Clinical Development Cell Therapy at Bristol Myers Squibb, with extensive experience in hematology and oncology drug development.
Company
Eric Bleickardt currently works at Bristol Myers Squibb as the Vice President of Late Clinical Development Cell Therapy. Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to treat severe diseases.
Title
Eric Bleickardt holds the title of Vice President, Late Clinical Development Cell Therapy at Bristol Myers Squibb. In this role, he contributes to the development and advancement of cell therapy treatments within the company.
Education and Expertise
Eric Bleickardt has an extensive educational background in medicine and biology. He earned his MD from Rutgers Robert Wood Johnson Medical School and completed his Internal Medicine Residency Program at Beth Israel Deaconess Medical Center. He further specialized in Medical Oncology and Hematology at Yale School of Medicine. His expertise lies in hematology and oncology drug development, with significant experience in immuno-oncology and cellular therapy.
Background
Eric Bleickardt has a robust background in the pharmaceuticals industry, particularly in the field of hematology and oncology. He has held multiple key positions at Bristol Myers Squibb, including Clinical Development Team Lead, Early Clinical Development Program Lead, and Group Director for Immuno-Oncology Hematology Clinical Development Team. He also served as Global Program Clinical Head at Novartis, overseeing clinical programs in East Hanover, New Jersey.
Achievements
Eric Bleickardt has played a pivotal role in overseeing the development of CAR-T therapies for lymphoma, multiple myeloma, and leukemia. He has significantly contributed to the advancement of notable therapies such as BREYANZI®️ and ABECMA®️. His efforts in development strategy, execution, and regulatory filing have been instrumental in progressing immuno-oncology and cellular therapy treatments.